FREJA is proud to announce that we in Denmark have extended our GMP permit to include EU release of medicines produced in third countries, i.e. outside of Europe. The EU release is a requirement before medicines can be sold on the European market.
[caption id="attachment_18481" align="alignright" width="225"]
Kiki Baagøe Andersen - QA Manager, QP, RP in FREJA[/caption]
The permit means that our customers can send medicines directly from third countries to FREJA, after which FREJA's QP (Qualified Person), Kiki Baagøe Andersen, will perform a Batch certification. Prior to the release of the products, FREJA's QP ensures that the products are analyzed in the EU according to current regulations. After this, FREJA will handle the delivery of the products to wholesalers, hospitals, or named doctors working on clinical trials. For you as a customer, this means that you do not need to hire an external QP consultant to perform the Batch certification, meaning you save time and money.
“We have been working on getting the permit since March, and we are incredibly proud that we can now offer this service. We are constantly looking for new ways in which we can create extra value for our customers, and we are confident that this new service will benefit our customers”, Marina Steensen, Group Healthcare Logistics Director, Denmark, says.
The permit applies to all non-sterile human and veterinary medicinal products, as well as non-sterile medicinal products for clinical trials for both human and veterinary products.
If you want to know more, please feel free to contact Marina Steensen or call your local contact person at FREJA.